廣告
香港股市 已收市

  • 恒指

    17,651.15
    +366.61 (+2.12%)
     

  • 國指

    6,269.76
    +149.39 (+2.44%)
     

  • 上證綜指

    3,088.64
    +35.74 (+1.17%)
     

  • 滬深300

    3,584.27
    +53.99 (+1.53%)
     

  • 美元

    7.8281
    +0.0003 (+0.00%)
     

  • 人民幣

    0.9251
    +0.0008 (+0.09%)
     

  • 道指

    38,239.66
    +153.86 (+0.40%)
     

  • 標普 500

    5,099.96
    +51.54 (+1.02%)
     

  • 納指

    15,927.90
    +316.14 (+2.03%)
     

  • 日圓

    0.0492
    -0.0009 (-1.74%)
     

  • 歐元

    8.3707
    -0.0275 (-0.33%)
     

  • 英鎊

    9.7780
    -0.0140 (-0.14%)
     

  • 紐約期油

    83.66
    +0.09 (+0.11%)
     

  • 金價

    2,349.60
    +7.10 (+0.30%)
     

  • Bitcoin

    63,855.80
    -766.51 (-1.19%)
     

  • CMC Crypto 200

    1,332.02
    -64.52 (-4.62%)
     

McKesson Boosts FY23 Outlook Backed By Strong Contribution From COVID-19 Drugs

Vandana Singh
·1 分鐘文章

  • McKesson Corp (NYSE: MCK) reported Q1 FY23 adjusted EPS of $5.83, +5% Y/Y, beating the consensus of $5.27.

  • Revenues increased 7% Y/Y to $67.15 billion, surpassing the consensus of $65.14 billion.

  • U.S. Pharmaceutical segment's revenues were $56.9 billion, +14%, driven by an increased volume of specialty products, including higher volumes from retail national account customers, and market growth, partially offset by branded to generic conversions.

  • Prescription Technology Solutions segment revenues increased 21% to $1.1 billion, driven by volume growth related to biopharma services.

  • Medical-Surgical Solutions revenues improved 3% to $2.6 billion, driven by growth in the primary care business, partially offset by lower sales of COVID-19 tests.

  • The company renewed its partnership with the U.S. government with the COVID-19 vaccine distribution contract extended through July 2023. The kitting, storage, and distribution of ancillary supplies contract have been extended through January 2023.

  • McKesson has settled or reached agreements to settle the opioid-related claims of all 50 states, the District of Columbia, and all eligible territories.

  • Outlook: McKesson raised the FY23 adjusted EPS forecast to $23.95 - $24.65 (consensus of $23.35), up from the previous guidance of $22.90 - $23.60

  • The updated outlook includes $0.35 - $0.45 related to the U.S. government's COVID-19 vaccine distribution, kitting, and storage programs; and $0.75 - $0.95 pertaining to COVID-19 tests.

  • Price Action: MCK shares closed at $327.10 on Wednesday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.